Extra Credit Educational Sessions & Hands-on Course

Objectives:

By participating in this learning program, health care providers can expect to:

• Understand why timing matters in referral
  Describe how delays in patient identification, imaging planning, and referral in mCRPC can limit access to radioligand therapy and reduce future treatment options.
• Identify which patients should be referred
  Differentiate between patients requiring immediate referral and those who benefit from early referral planning based on disease stage, prior therapies, and anticipated progression.
• Apply a practical referral approach
  Implement a structured, proactive referral strategy that supports coordination with specialized centers, timely imaging, and multidisciplinary alignment.

Objectives:

By participating in this learning program, health care providers can expect to:

• Identify clinical considerations to optimize outcomes for patients with high-risk, BCG-unresponsive NMIBC in routine practice.
• Balance data-driven decision-making with patient preferences in an evolving treatment landscape.
• Understand the gap between real-world practice and guideline recommendations, and the impact of this gap on patient outcomes.

Objectives:

By participating in this learning program, health care providers can expect to:

• Apply real-world evidence to optimize systemic therapy for mCSPC, including timely treatment intensification, appropriate referrals and testing, and routine safety and adherence management.
• Recognize the importance of proactive treatment approaches in reducing therapeutic inertia and supporting coordinated care across urology and oncology.
• Describe how clinical guidelines inform the management of mCSPC, including treatment intensification strategies.

By participating in this learning program, health care providers can expect to:

• Re-evaluate advanced diagnostic and risk stratification modalities in NMIBC
• Discuss patient selection criteria for bladder-sparing therapies in high-risk NMIBC
• Apply best practices for the administration and follow-up of approved intravesical bladder-sparing treatments in Canada